# Opdivo (nivolumab)

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/opdivo-nivolumab
Canonical HTML page: https://gethealthbrief.com/entity/opdivo-nivolumab

## Recent coverage (1 stories)

### Oncologists Worldwide Cut Opdivo Doses by up to 92%, Defying FDA's 1-Year Rule
2026-08-20 09:12:50 · Sentiment: Negative · Impact: 7/10 · Sources: 2

A growing movement of oncologists is testing lower or shorter courses of checkpoint inhibitors like Opdivo and Keytruda, challenging the FDA's fixed one-year protocol. For health systems, this raises urgent questions about clinical decision support, patient safety, and value-based oncology as real-world evidence mounts.
Full story: https://gethealthbrief.com/story/fda-cancer-drug-dosing-challenge-health-systems

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.